Contribution of HIV infection to mortality among cancer patients in Uganda

AIDS

Volumn 27, Issue 18, 2013, Pages 2933-2942

  Coghill, Anna E ^a,b,c   Newcomb, Polly A ^a,b   Madeleine, Margaret M ^a,b   Richardson, Barbra A ^a,b   Mutyaba, Innocent ^a   Okuku, Fred ^a   Phipps, Warren ^a,b   Wabinga, Henry ^d   Orem, Jackson ^a   Casper, Corey ^a,b  

^a Fred Hutchinson Cancer Research Center   (Uganda)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Kampala Cancer Registry   (Uganda)

Author keywords

Cancer in Africa; Cancer survival; HIV; Immunosuppression; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HIV TEST; HODGKIN DISEASE; HOSPICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UGANDA; UTERINE CERVIX CANCER; ADOLESCENT; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UGANDA; YOUNG ADULT;

EID: 84888299403     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000433236.55937.cb     Document Type: Article

References (77)

1. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-137.
2. Kasamba I, Baisley K, Mayanja BN, Maher D, Grosskurth H. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: A longitudinal populationbased study, 1999-2009. Trop Med Int Health 2012; 17:e66-e73.
3. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Intern Med 2011; 155:209-216.
4. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposis sarcoma and non-Hodgkins lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-1210.
5. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32:527-533.
6. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
7. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170:1337-1345.
8. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: Impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203-208.
9. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
10. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-890.
11. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
12. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 2011; 62:157-170.
13. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 2010; 126:1187-1195.
14. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 2000; 82:1585-1592.
15. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985-990.
16. Martin JBN, Bwama M, Muyindike W, Amerson E, Musick B, Wois-Kaloustain K. Prospective evaluation of the impact of ART on the incidence of KS-IDEA Consortium; 2012.
17. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999; 13:2563-2570.
18. Semeere AS, Busakhala N, Martin JN. Impact of antiretroviral therapy on the incidence of Kaposi sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol 2012; 24:522-530.
19. Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39:1380-1384.
20. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
21. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. AIDS 2009; 23: 41-50.
22. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194.
23. Chaabna K, Bray F, Wabinga HR, Chokunonga E, Borok M, Vanhems P, et al. Kaposi sarcoma trends in Uganda and Zimbabwe: A sustained decline in incidence Int J Cancer 2013; 133:1197-1203.
24. Bateganya MH, Stanaway J, Brentlinger PE, Magaret AS, Wald A, Orem J, et al. Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: A retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr 2011; 56:312-319.
25. Parkin DM, Wabinga H, Nambooze S. Completeness in an African cancer registry. Cancer Causes Control 2001; 12:147-152.
26. Goldman JS, Mutyaba I, Okuku F, Nambooze S, Wabinga H, Kristal A, et al. Measurement of the impact of antiretroviral therapy coverage on incidence for AIDS-defining malignancies in sub-Saharan Africa. Lancet 2011published online March 14.
27. Wabinga H, Ramanakumar AV, Banura C, Luwaga A, Nambooze S, Parkin DM. Survival of cervix cancer patients in Kampala, Uganda: 1995-1997. Br J Cancer 2003; 89:65-69.
28. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
29. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIVinfected individuals treated with antiretroviral therapy. AIDS 2010.
30. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60:183-189.
31. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897-904.
32. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823-2831.
33. van Leeuwen MT, Grulich AE, Webster AC, McCredie MR, Stewart JH, McDonald SP, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114:630-637.
34. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. J Am Med Assoc 2011; 306:1891-1901.
35. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:2551-2559.
36. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370:59-67.
37. Busnach G, Piselli P, Arbustini E, Baccarani U, Burra P, Carrieri MP, et al. Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006; 38:3533-3535.
38. Cobucci RN, Saconato H, Lima PH, Rodrigues HM, Prudencio TL, Junior JE, et al. Comparative incidence of cancer in HIVAIDS patients and transplant recipients. Cancer Epidemiol 2012.
39. Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43:2117-2123.
40. Vajdic CM, van Leeuwen MT. What types of cancers are associated with immune suppression in HIV Lessons from solid organ transplant recipients. Curr Opin HIV AIDS 2009; 4:35-41.
41. Kersten MJ, Klein MR, Holwerda AM, Miedema F, van Oers MH. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkins lymphoma. J Clin Invest 1997; 99:1525-1533.
42. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD4R and CD8R T cells in HIV-infected patients progressing to AIDSrelated non-Hodgkin lymphoma. Blood 2005; 106:3166-3174.
43. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(R) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001; 98:146-155.
44. Bihl F, Berger C, Chisholm JV 3rd, Henry LM, Bertisch B, Trojan A, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposis sarcoma. AIDS 2009; 23:1918-1922.
45. Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, et al. Kaposis sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposis sarcoma. AIDS 2007; 21:1245-1252.
46. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
47. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4R and CD8R T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011; 186:2106-2116.
48. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(R) and CD8(R) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-11991.
49. Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar RL, Natarajan V, et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4R and CD8R T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A 2000; 97:13778-13783.
50. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2005; 102:14807-14812.
51. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84:12971-12981.
52. van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett 2005; 97:19-29.
53. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8R T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2:E20.
54. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion Immunol Today 1997; 18:450-454.
55. Jin HT, Jeong YH, Park HJ, Ha SJ. Mechanism of T cell exhaustion in a chronic environment. BMB Rep 2011; 44:217-231.
56. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-7561.
57. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97:192-197.
58. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192:755-760.
59. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
60. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50.
61. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
62. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-365.
63. Wang RF, Rosenberg SA. Human tumor antigens recognized by T lymphocytes: Implications for cancer therapy. J Leukoc Biol 1996; 60:296-309.
64. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8RT cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-3494.
65. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 2010; 29:1093-1102.
66. Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, et al. Association of CD8(R) T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol 2011; 164:50-56.
67. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(R) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61:3932-3936.
68. Deeks SG. HIV Infection, Inflammation, Immunosenescence, and Aging. Annu Rev Med 2011; 62:141-155.
69. Decrion AZ, Dichamp I, Varin A, Herbein G. HIV and inflammation. Curr HIV Res 2005; 3:243-259.
70. Keating SM, Golub ET, Nowicki M, Young M, Anastos K, Crystal H, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women. AIDS 2011.
71. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
72. Bastard JP, Soulie C, Fellahi S, Haim-Boukobza S, Simon A, Katlama C, et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012.
73. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
74. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow Lancet 2001; 357:539-545.
75. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
76. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
77. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.